Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1983 Jan;51(1):91–98.

Impaired opsonization by serum from patients with chronic liver disease.

R J Wyke, I A Rajkovic, R Williams
PMCID: PMC1536747  PMID: 6339126

Abstract

Serum opsonization of two organisms, E. coli and yeasts (S. cerivisiae), was examined in 68 patients with chronic liver disease (CLD). Impaired opsonization for yeasts was found in seven (29%) of 24 patients with chronic active hepatitis, six (27%) of 22 with alcoholic cirrhosis and five (23%) of 22 with primary biliary cirrhosis. Opsonization for E. coli was normal in patients with primary biliary cirrhosis but impaired in seven (29%) patients with chronic active hepatitis and three (14%) of those with alcoholic cirrhosis. The defect of opsonization in chronic active hepatitis was found mainly in patients with histological evidence of active disease. A deficiency, rather than antagonism or inhibition, of normal opsonization factors was responsible, but could not be related to reduced levels of serum complement factors of either the classical or the alternative pathway present in 45% of the patients with chronic active hepatitis, 71% with alcoholic cirrhosis and 18% of those with primary biliary cirrhosis. Serum from two of 11 patients with impaired opsonization antagonised the function of normal polymorphonuclear leucocytes, and polymorphonuclear leucocytes from six of seven patients had slightly reduced phagocytosis/killing of E. coli opsonized in normal serum. Defects of serum opsonization, complement activity and polymorphonuclear leucocyte function may be causes of the increased susceptibility to bacterial infection in patients with CLD.

Full text

PDF
91

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alper C. A., Colten H. R., Rosen F. S., Rabson A. R., Macnab G. M., Gear J. S. Homozygous deficiency of C3 in a patient with repeated infections. Lancet. 1972 Dec 2;2(7788):1179–1181. doi: 10.1016/s0140-6736(72)92598-6. [DOI] [PubMed] [Google Scholar]
  2. Campbell A. C., Dronfield M. W., Toghill P. J., Reeves W. G. Neutrophil function in chronic liver disease. Clin Exp Immunol. 1981 Jul;45(1):81–89. [PMC free article] [PubMed] [Google Scholar]
  3. Iscaki S., Buffet C., Briantais M. J., Geneste C., Etienne J. P., Pillot J. IgA sécrétoires sériques dans les maladies hépatiques et dans diverses situations physiologiques ou pathologiques humaines. Gastroenterol Clin Biol. 1981 Mar;5(3):305–313. [PubMed] [Google Scholar]
  4. Jones E. A., Sherlock S., Crowley N. Bacteraemia in association with hepatocellular and hepatobiliary disease. Postgrad Med J. 1967 Mar;43(Suppl):7–11. [PubMed] [Google Scholar]
  5. Kourilsky O., Leroy C., Peltier A. P. Complement and liver cell function in 53 patients with liver disease. Am J Med. 1973 Dec;55(6):783–790. doi: 10.1016/0002-9343(73)90259-3. [DOI] [PubMed] [Google Scholar]
  6. Martin A., Lachmann P. J., Halbwachs L., Hobart M. J. Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry. 1976 Apr;13(4):317–324. doi: 10.1016/0019-2791(76)90341-4. [DOI] [PubMed] [Google Scholar]
  7. Quie P. G., White J. G., Holmes B., Good R. A. In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood. J Clin Invest. 1967 Apr;46(4):668–679. doi: 10.1172/JCI105568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Soothill J. F., Harvey B. A. A defect of the alternative pathway of complement. Clin Exp Immunol. 1977 Jan;27(1):30–33. [PMC free article] [PubMed] [Google Scholar]
  9. Tauber A. I. Current view of neutrophil dysfunction: an integrated clinical perspective. Am J Med. 1981 Jun;70(6):1237–1236. doi: 10.1016/0002-9343(81)90833-0. [DOI] [PubMed] [Google Scholar]
  10. Van Epps D. E., Williams R. C., Jr Suppression of leukocyte chemotaxis by human IgA myeloma components. J Exp Med. 1976 Nov 2;144(5):1227–1242. doi: 10.1084/jem.144.5.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Van Oss C. J., Gillman C. F. Phagocytosis as a surface phenomenon. II. Contact angles and phagocytosis of encapsulated bacteria before and after opsonization by specific antiserum and complement. J Reticuloendothel Soc. 1972 Nov;12(5):497–502. [PubMed] [Google Scholar]
  12. Wyke R. J., Rajkovic I. A., Eddleston A. L., Williams R. Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure. Gut. 1980 Aug;21(8):643–649. doi: 10.1136/gut.21.8.643. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES